SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a next-generation PD-1-inhibiting cytokine, a proprietary technology designed to improve on the efficacy of CAR T therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group.
Biotechnology Research, Medical and pharmaceutical research, Research and testing, IT, Internet, R&D, Research, general, Chemistry, physics and biological engineering consultants, Technical offices and engineering consultancies, architects, Biotechnology research and development, Immunology research and development